Welcome to Gentech
As a biotechnology manufacturer, Gentech is committed to advancing scientific research to develop innovative biologics that can improve human health. We seeks to break the boundaries of science to bring about good to humankind. Our mission is to bring breakthrough scientific medicine at affordable prices to serve our patients and community.
We have a dedicated team of researchers and scientists who work tirelessly to discover new ways to treat diseases that plague our society. Our laboratory and manufacturing strive continuously to ensure that we produce world-class quality, safe and efficacious biologics. Our support staff are committed to deliver excellent support services to ensure the life-saving biologics are delivered to our patients. We are passionate about our work and strive to make a difference in the lives of people around the world.
Image credit:
Image by <a href="https://www.freepik.com/free-photo/adorable-mature-women-together_6057790.htm">Freepik</a>
<a href="https://www.vecteezy.com/free-photos">Free Stock photos by Vecteezy</a>
<a href="https://www.freepik.com/free-photo/elderly-friends-playing-petanque_27642744.htm#query=old%20friends&position=2&from_view=search&track=ais">Freepik</a>
​<a href="https://www.freepik.com/free-photo/family-sitting-garden-with-apples_7397067.htm#page=2&query=women_family-sitting-garden-with-apples&position=41&from_view=search&track=ais">Image by prostooleh</a> on Freepik
Management Team
Katherine Liew-Tan
CEO & Market Researcher
Our team is led by Katherine Liew-Tan, who serves as our CEO and Market Researcher. Katherine has many years of experience managing biotechnology companies, and has a proven record of bringing delivering profitability and double-digit growth. She has also extensive market research experience in the industry and has brought over 23 new commercialised innovations to market.
Contact Katherine via Linkedin
Vikneswari Rajasegaran
Laboratory Researcher
Vicki is our scientist who leads a passionate group in the R&D team, making scientific discovery and innovations together to improve the lives of patients with more efficient therapeutics. She also researches on improving the pipeline productivity. She has extensive experience in developing and establishing molecular diagnostic platform and profiled numerous breast cancer subtypes.
​
​
Contact Vikneswari via Linkedin
Rachel Shu Bin Ong
Facilities Manager
Rachel is a Facilities Manager with over 4 years of relevant laboratory management background in areas of occupational hazard and safety control. She oversees the operational aspects of the company's facilities, ensuring they function smoothly and efficiently through managing maintenance, safety, and space utilization to create a conducive work environment for all our fellow employees here at Gentech.
Contact Rachel via Linkedin
Ga Angelica Faye Santos
Laboratory Manager
Faye is a highly skilled Lab Manager with 5 years of extensive experience in overseeing daily operations, optimizing efficiency and ensuring compliance with industry standards. She is an expert in managing cross-functional teams, maintaining and implementing quality control systems and developing strategies to improve laboratory performance. Here in Gentech, she continues to focus on continuous improvement to foster a culture of excellence.
Contact Faye via Linkedin
Management Team Introduction
Biotech Business Model
Key Activities
Key activities are in the designing, manufacturing, and delivering of a high-quality functioning monoclonal antibody to patients.
Design
The development stage has been done in the last 10 years with clinical trial support for Herceptini trastuzumab’s efficacy and safety, as well proper documentations in lab conditions.
Manufacturing
The production has been scaled up to a manufacturing facility. The important activities in manufacturing are:
Strict GMP (Good manufacturing practice) clean-room manufacturing procedures, protocol and documentations for Herceptini trastuzumab mAb production.
Validations, Monitoring and controls in each step of protein generation and downstream processing to ensure appearance, identity, concentration, purity and potency of the final properly folded functioning protein is accounted for.
Quality control check and validations on the final product lot/batch.
Logistics and supply chain infrastructure
Strict management of storage and shipment environment and conditions.
Strong Branding
Brand and product awareness, trust and usage amongst oncogenic experts and target HER2+ breast cancer patients.
Stakeholders
-
Strategic alliance: Roshe pharmaceutical company.
-
Strategic alliance: PCI Biopharma on humanised monoclonal antibody production method.
-
Buyers: distributed hospitals (oncogenic doctors and procurement) that provide breast cancer treatment to target patients.
-
Suppliers: raw materials, lab and manufacturing plan equipment and materials and packaging, storage, and shipping.
Value Proposition
-
HERCEPTINI® trastuzumab is the first humanised monoclonal antibody in the medical field
-
Targets Gentec discovered HER2 oncogene which causes the most aggressive breast cancer (HER2+ subtype).
-
An adjuvant treatment that delivers significant better patient outcomes (e.g. survival, time to disease progression) than chemotherapy monotherapy.
Potential Funding Sources
-
Strategic alliance: Roshe pharmaceutical company.
Major Costs
-
Value-driven costs to provide maximum value to patients.
-
Fixed (Lab and manufacturing equipment, facilities rental, indirect staff payroll, insurance, property tax)
-
Discretional fixed costs (R&D costs, Clinical trials costs)
-
Variable costs (Cost of goods related, e.g. raw materials, packaging, direct labour, utilities, storage & shipping, sales & distribution cost paid to Roshe pharmaceutical company, royalties to PCI Biopharma)
Revenue Streams
-
Transaction-based revenue derived from sales of Herceptini trastuzumab that is distributed through hospitals.
-
The revenue is generated throughout the course of patient’s 12-month treatment.